Rationale: Gene delivery applications to treat lung diseases are, in some instances, sub-optimal due to deleterious host inflammatory reactions. Current DNA plasmids (pDNA) exert toxicity in part via unmethylated CpG motifs that stimulate TLR9 expressing leukocytes; however the airway epithelial response has not been well defined. Methods: Bronchial epithelial cells (BEAS-2B) were exposed to pDNA complexes and inflammatory mediators were measured. As patients with inflammatory lung disease are susceptible to infectious exacerbations, we also evaluated the reciprocal inflammatory response to pDNA and bacterial components LPS and LTA, recognised by TLR4 and TLR2 respectively. Results: Cells primed with pDNA synergistically expressed IL-8 mRNA and protein in response to LPS and LTA (3-5 fold). A similar induction was also observed for IL-1β, IL-6, CSF-1 and GM-CSF. Their synergistic elevation was associated with an increase in TLR4 and TLR2 levels.
Introduction:
Gene transfer therapy is of great interest not only to monogenetic lung diseases such as cystic fibrosis (CF) but also asthma and COPD, since the airway epithelium is accessible to non-invasive delivery modes (1) . It is also technical feasible with current methods to formulate and deliver such aerosolised agents to the upper or lower airways as required (2) . Viral vectors are an attractive delivery vehicle as they can transfect terminally differentiated cells and typically result in robust gene expression required for a clinical benefit. While host humoral antibody responses are not as limiting as initially believed, gene therapy vectors may still elicit deleterious inflammatory responses that may lessen their therapeutic utility (3) (4) (5) .
Plasmid DNA (pDNA) vectors are considered to be a safer and less immunogenic gene delivery agent as they generally induce a weaker host response. Lipid-mediated transfer of pDNA has successfully been introduced into human airways (6) and GFP tagging experiments in murine lung have identified the respiratory epithelium as the major cellular target (7) . Unfortunately, the current generation of cationic lipid-DNA delivery agents tested in CF airways have not resulted in any clinical benefit, as expression of the target gene in the conducting airways is suboptimal (6) . Lipid-DNA complexes delivered via nasal or lung routes were reported to elicit significant side effects including transient flu-like symptoms associated with elevated IL-6 levels induced by the host's immune response (6, 8, 9) . The presence of unmethylatated CpG motifs in DNA vectors are thought to drive pDNA mediated inflammatory events (10) . CpG motifs are common in the prokaryotic genome and are recognised as a pathogen associated molecular pattern (PAMP). The recognition of PAMPs is facilitated by a family of evolutionarily conserved pathogen recognition receptors known as Toll-Like Receptors (TLR) (11) .
There are at least ten human TLRs; each recognises unique microbial PAMPs. Upon PAMP engagement, TLRs trigger multiple signalling cascades that activate the transcriptional factors, NFκB Page 4 of 23 and AP-1, which promote expression of key inflammatory mediators. The neutrophil chemokine, IL-8 cooperates with cytokines like TNFα and IL-6 to coordinate recruitment of neutrophils, which typically destroy the invading pathogen via potent proteases and oxidative free radicals.
Discrete cellular distribution and localisation of specific TLRs are thought to limit the deleterious effects associated with acute inflammatory responses. TLR2 recognises numerous PAMPs including Lipoteichoic acid (LTA) expressed on gram positive bacteria and TLR4 is the stereotypic Lipopolysaccrharide (LPS) receptor engaged by gram negative bacteria. TLR9 is responsible for recognising unmethylated CpG motifs and like TLR4 (12), is thought to be localised in intracellular endocytic compartments to avoid persistent activation by luminal commensal bacteria (13). Although alveolar macrophages have traditionally been viewed as the primary professional airway innate immune cell-type, the respiratory epithelium expresses a comprehensive suite of TLRs including TLR1-6 and 9 (14, 15) . Importantly, targeted disruption of NFκB signalling in the airway epithelium prevents lung inflammation and injury resulting from local or systemic administration of LPS (16) .
Since CF and emphysema airways are typically colonised with bacteria normally absent in healthy lungs, and patients with chornic inflammatory lung diseases are highly susceptible to exacerbations triggered by infection, TLR interactions may contribute to the pathogenesis of these conditions. TLR reciprocation has been implicated in augmented inflammatory responses as co-stimulation of macrophages or dendritic cells (DC) with LPS and CpG-DNA synergize the release of inflammatory cytokines (17) (18) (19) . CpG-DNA and IL-1β also synergistically elevate IL-8 release from bronchial epithelial cells (20) .
The cytokine response to cationic lipid-DNA complexes is not well characterised in airway epithelial cells. This response occurs rapidly, promotes recruitment of phagocytic cells to the airways and contributes to reduced transgene expression. In diseased airways, inflammation is compounded by the persistence of colonising bacterial strains. Since the bronchial epithelium is capable of mounting TLR-dependent inflammatory responses, targeted disruption of epithelial signalling may improve transgene expression and reduce the overall inflammatory burden associated with chronic lung diseases. The signalling modules responsible for NFκB driven cytokine production in respiratory epithelium are cell-type specific (21) and refractory to conventional anti-inflammatory agents such as glucocorticosteroids (22). Recently, LPS induced IL-8 production was shown to be regulated by a novel airway epithelial signalling cascade that requires ligand-mediated activation of the epidermal growth factor receptor (EGFR) (21) . EGFR is typically expressed in intercellular lateral epithelial junctions (23) and is transiently induced at sites of damage to coordinate epithelial repair mechanisms (24). EGFR may also regulate neutrophil recruitment through IL-8 in order to clear cellular and pathogenic debris. However, EGFR expression appears to be deranged in CF, emphysema and asthma airways due to their chronic nature and may contribute to persistent pathogenic processes (25-27).
Indeed, a positive correlation between EGFR, IL-8 and submucosal neutrophils in asthmatic bronchial biopsies has been demonstrated (28).
In this study we investigated inflammatory mechanisms triggered by pDNA in BEAS-2B bronchial epithelial cells. We found that lipid-pDNA complexes were modestly pro-inflammatory. However when combined with LPS or LTA, pDNA primed epithelial cells responded by synergistically increasing IL-8 production. Signalling mechanisms were evaluated using selective pharmacological inhibitors to EGFR (AG1478), Erk (U0126) and p38 (SB203580) MAPKs, identifying EGFR as a central signalling pathway responsible for exaggerated inflammation in pDNA primed bronchial cells.
Furthermore, lipid-pDNA complexes augment cytokine and chemokine responses by upregulation of TLR4 and TLR2 expression via EGFR dependent mechanisms. We suggest that inhibition of the
METHODS
Cell Culture. Human BEAS-2B cells were obtained from ATCC (Rockville MD) and were cultured in a 1:1 mixture of keratinocyte−serum-free medium supplemented with 50 mg/ml of bovine pituitary extract and 5 µg/ml of epidermal growth factor, and Minimum Essential Medium (MEM) supplemented with 10% FCS, 2 mM L-glutamine, 1.0 mM sodium pyruvate, 0.1 mM non-essential amino acids, and 1.5 g/L sodium bicarbonate and antibiotics (25 µg/ml gentamicin, 100 µg/ml penicillin, 100 µg/ml streptomycin). All cell culture medium and supplements were purchased from Invitrogen.
Plasmid DNA treatment and methylation of vector. pcDNA1/Amp vector (Invitrogen) was purified using Endofree plasmid Giga kit (Qiagen). BEAS-2B cells were plated out in 6-well multidishes for 24 Hrs prior to treatment. Cells were treated with liposome-pDNA (0.8µg pDNA) using Effectene (Qiagen) in accordance to the manufacturers' instruction. Lipid-pDNA exposure was carried out in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 5% FCS and 25 µg/ml gentamicin.
Where indicated, pDNA was also methylated at CpG sites using 4U of CpG methylase (SssI, New England Biolabs) per microgram of pDNA in a reaction containing 160 µM S-adenylmethionine as a methyl donor for 2 Hrs at 37°C. At the end of the reaction, the enzyme was removed using Wizard DNA clean-up system (Promega) following manufacturers' instructions, and resuspended in endotoxin-free TE buffer. To confirm methylation, pDNA was digested with HpaII restriction enzyme, which digests only unmethylated CpG sequences.
LPS and LTA challenge following lipid-pDNA exposure and use of selective pharmacological inhibitors. For secondary challenge, cells were first rinsed with PBS and then stimulated with LPS (1ng/ml, from Salmonella enterica Re 595) and LTA (1µg/ml, from Staphylococcus aureus) (SigmaAldrich) in DMEM supplemented with 1% FCS and 25 µg/ml gentamycin. In indicated experiments, cells were treated with the EGFR inhibitor AG1478 (10 µM; Biomol), the ERK 1/2 inhibitor U0126 (10 µM; Cell Signalling Technology), and the p38 inhibitor SB203580 (10 µM; Sigma). The GM-CSF neutralizing antibody (0.5 µg/ml; R&D Systems) and corresponding IgG isotype were also used.
Quantification of IL-8 protein.
Cell-free supernatants were collected and IL-8 concentration was measured using commercially available paired antibodies and standards, following the manufacturer's instructions (BD Pharmingen).
RNA extraction and Quantitative Real-time PCR (QPCR).
Total RNA was isolated from individual samples, according to the manufacturer's instructions, using the RNeasy kit (Qiagen). The purified RNA was used as a template to generate first-strand cDNA synthesis using SuperScript III (Invitrogen) as previously described (29). QPCR was performed using the ABI PRISM 7900HT sequence detection system (Applied Biosystems). For mRNA quantitation, Taqman probe/primer combinations were used. A total volume of 10µl was used for Taqman PCR using AmpliTaq Gold polymerase and universal master mix (Applied Biosystems). The threshold cycle numbers were calculated using the ∆∆CT relative value method and normalised to 18S rRNA. 8-fold) and GM-CSF (14-fold), whereas no significant change in basal IL-1β was observed (Figure 3A-D) . LPS-induced transcript levels were synergistically increased in pDNA primed cells, ranging from 1.5 to 6-fold above LPS alone. Since GM-CSF is an integral mediator of lung inflammation and is known to regulate TLR4 expression (29, 30), we postulated that enhanced basal GM-CSF may contribute to elevated basal TLR4 expression.
Hence, we measured TLR4 and TLR2 levels by QPCR and observed a significant increase in basal TLR4 (3.5-fold) and TLR2 (2-fold) expression in lipid-pDNA primed cells, as shown in Figure 4 .
Blocking GM-CSF bioactivity from pDNA primed cells with a neutralising antibody did not restore normal basal TLR4 or 2 expression (data not shown), implicating novel mechanisms of pDNA mediated TLR upregulation. Hence, pharmacological inhibitors of EGFR, Erk and p38 MAPKs were evaluated. Here, epithelial cells were treated with the EGFR (AG1478), Erk (U0126) or p38 (SB203580) inhibitors for 3Hrs following pDNA exposure and TLR4 and TLR2 expression was assessed by QPCR. The EGFR and Erk inhibitor reduced TLR4 and TLR2 expression to basal levels as seen in untreated cells, whereas p38 inhibition selectively reduced TLR2 levels only ( Figure 5A-B) . 
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The p38 inhibitor, SB203580 was also effective at reducing augmented IL-8 production attributed to pDNA priming. Since the p38 inhibitor did not alter TLR4 expression, our results suggest that p38 MAPK signalling is not regulating TLR4 levels but an important downstream mediator of TLR driven inflammatory processes. This is consistent with previous reports that implicate p38 as an integral regulator of post-transcriptional mechanisms responsible for IL-8 mRNA stability and protein expression (31).
Discussion
Acute inflammatory responses are known to significantly reduce transgene expression, an event that becomes more apparent with secondary applications (4). Suppression of transgene expression is caused by induction of inflammatory cytokines known to attenuate promoters/enhancers common to viral and non-viral vectors (32). Current strategies to limit this inflammatory response include the construction of plasmid sequences with reduced CpG content, which significantly dampens innateimmune mediated inflammation (33, 34). However, CpG depletion in typical promoter regions can reduce transgene expression, which limits the utility of such applications. Likewise, global methylation of CpG containing vectors reduce TLR9-mediated inflammatory events (35) , however since most promoters are negatively regulated by methylation, reduced transgene expression is typically prevalent. Furthermore, our results show that methylation of pDNA-liposome complexes only partially reduce IL-8 release from bronchial epithelial cells. Previous reports also describe CpG/TLR9 independent induction of inflammatory cytokines (36, 37) and TLR9 deficient mice display significant toxicity to lipid-pDNA complexes, although the overall inflammatory burden was reduced (38) . BEAS-2B cells also express low TLR9 levels and hence respond to CpG oligonucleotides very modestly (15) . Since we observed a 7-fold induction in IL-8 release, pDNA appears to be targeting an alternative inflammatory cascade in BEAS-2B cells.
Another approach to reducing pDNA-mediated immunity involves the use of anti-inflammatory drugs such as glucocorticosteroids. These agents reduce the toxicity associated with systemic administration of lipid-pDNA complexes and importantly, can improve transgene expression when administered prophylactically (39) . A novel approach to gene delivery involves the co-administration of steroids encapsulated within the liposome-pDNA complex, thereby localising both vector and steroid to the cellular targets (40) . However, a likely caveat of treating lung diseases with such an approach is that lung inflammatory events can be particularly refractory to conventional steroid treatment (41) .
Intravenous delivery of high dose steroids may improve their efficacy, but are associated with significant side-effects. Hence, the benefit of encapsulating steroids within aerosolised liposome-DNA complexes may be compromised in the chronically inflamed CF and COPD lung microenvironment. Our findings also describe the cooperative nature of pathogen recognition receptors, since bronchial epithelial cells primed with pDNA synergistically express key inflammatory mediators in response to TLR4 and TLR2 agonists. This observation highlights the difficulty of introducing gene delivery agents to CF or COPD lungs that are readily colonised by pathogenic bacteria and may provide novel insights into the pathogenesis of these chronic lung diseases. For example, since pDNA can act as a surrogate for bacterial DNA, which is abundantly present in CF and COPD sputum, infectious exacerbations may be worsened by bacterial DNA priming events.
These acute episodes are associated with an increased local and systemic inflammatory burden that is poorly tolerated in individuals with reduced lung reserve capacity (42) . Hence, the persistence of bacterial DNA fragments in CF and COPD airways may contribute to excessive inflammatory responses to new bacterial pathogens by priming TLR signalling pathways that control cytokine and chemokine gene programs.
In this study, we identified EGFR signalling as a novel mechanism responsible for pDNA priming of bronchial epithelial cells as AG1478 completely inhibited pDNA-mediated upregulation of TLR4/2 levels and associated IL-8 release in response to LPS and LTA. Transactivation of EGFR is controlled by ligand engagement, which promotes formation of homodimeric and heterodiomeric receptor complexes (EGFR/HER2) (43) . Upon activation, EFGR is phosphorylated at specific intracellular residues that become docking sites for the recruitment of downstream signalling molecules. There are three major pathways engaged by EGFR transactivation (43) . Erk MAPK is activated through a series of intermediate kinases and docking modules such as the Grb/Sos complex. Once activated, Erk promotes inflammatory gene expression via the AP-1 transcription factor complex consisting of Jun, Fos and ATF-2 dimers that are regulated by MAPK-mediated phosphorylation. To assess the role of Erk MAPK in pDNA primed inflammatory processes, the selective inhibiter U0126 was used, which displayed a similar inhibitory profile to the EGFR blocker. In contrast, p38 MAPK did not suppress TLR4 expression, hence may coordinate inflammation via stabilisation of transcription and protein expression (31). A secondary pathway involves the STAT transcription factor family, which also induces gene expression (44) . To evaluate STAT activation, we transiently expressed kinase-inactive EGFR (K721R), which is selectively deficient in STAT signalling whilst retaining Erk and Akt activation (45, 46) . Over-expression of the EGFR-K721R mutant did not interfere with pDNA priming responses (data not shown). The PI3K/Akt pathway is also engaged during EGFR transactivation. Akt is a pleiotropic kinase that regulates cell survival, glucose metabolism, protein synthesis and NFκB-mediated gene expression in a cell type and stimuli specific manner. However, the PI3K inhibitor, Wortmannin, did not suppress the IL-8 release from LPS or LTA cells (data not shown). Consistent with our findings, Nakanaga and colleagues also describe a novel EGFR dependent signalling pathway responsible for IL-8 release in bronchial epithelial cells (21) . 
